Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs AR 101 (Primary) ; Dupilumab (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 28 Oct 2021 Status changed from active, no longer recruiting to completed.
- 09 Mar 2021 Planned End Date changed from 30 Jun 2021 to 6 Oct 2021.
- 20 Jul 2020 Planned End Date changed from 11 Aug 2021 to 30 Jun 2021.